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Background: Staphylococcus aureus is an important pathogen in CF. Centre prevalence of intermittent colonization and chronic S. aureus
infections and the effectiveness of an anti-S. aureus eradication strategy was assessed.
Methods: All airway cultures from 300 patients in a 2-year period were retrieved and all anti‐S. aureus antibiotic treatments were evaluated for
treatment success. Chronic infection was deﬁned as a positive culture of S. aureus in 50% or more of the months each year. Change in FEV1
following 2weeks of treatment of S. aureus was assessed in clinically stable patients. Primary outcome was S. aureus eradication at next clinical
visit and number of patients chronically infected.
Results: The yearly prevalence of S. aureus intermittent and chronic infection was 47% and 14%, respectively. Eradication was successful at the
next clinical visit in 61% of the standard treatment and 53% of the prolonged treatments, respectively. FEV1 improved signiﬁcantly following anti-
S. aureus treatment (3.3%, pb0.0001).
Conclusion: Our anti-S. aureus eradication strategy in CF patients resulted in a low prevalence of chronic infections and high treatment efﬁcacy.
Furthermore, anti-staphylococcal treatment may be associated with a short-term improvement in lung function.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: MRSA; MSSA; Anti-staphylococcus treatment; Treatment effectiveness; Cystic ﬁbrosis1. Introduction
Infections with Pseudomonas aeruginosa and other Gram-
negative rods are associated with deterioration in lung function☆ Part of this work was presented at the 24th Annual North American Cystic
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Staphylococcus aureus Infection in Patients with Cystic Fibrosis at the
Copenhagen CF Centre” and as an oral presentation and a poster “Impact of
Prophylactic Antibiotics for Respiratory Tract Colonization with Staphylococcus
aureus on Lung Function and BMI in CF Patients Without Acute Exacerbation”.
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1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.06.005and increased morbidity and mortality eventually leading to
end stage lung disease [1]. Several studies have demonstrated
that pulmonary inflammation is evident soon after diagnosis
and that known CF airway pathogens such as, S. aureus and
P. aeruginosa, are the most commonly detected bacteria [2].
Aggressive treatment of infections, in particular those due to
P. aeruginosa, has been shown to decrease pulmonary in-
flammation [3]. Furthermore a significant association between
early lower respiratory tract infection with S. aureus and
increased inflammation together with decreased body mass
index (BMI) z-scores has been reported [4]. While treatment of
P. aeruginosa infection is clearly important, infection with
S. aureus and efforts to treat this organism more aggressively
need to be investigated as well as the clarification of risk for theby Elsevier B.V. All rights reserved.
43C.S. Dalbøge et al. / Journal of Cystic Fibrosis 12 (2013) 42–48selection of Gram‐negative bacteria such as P. aeruginosa from
such a treatment [5,6].
A particular aspect of chronic infection with S. aureus is the
appearance of small colony variants (SCV). There is evidence
that exoproducts of P. aeruginosa enhance SCV formation as
well as long-term systemic aminoglycoside and trimethoprim–
sulfamethoxazole treatments [7]. SCV are associated with
higher rates of antimicrobial resistance and more advanced lung
disease in CF [8,9].
The purpose of this study was to assess the prevalence of
intermittent and chronic S. aureus infections, including the
incidence of MRSA, and evaluate the effectiveness of the
anti-S. aureus treatment regimens currently used in our center.
This strategy has been unchanged since the establishment of the
CF centre in 1968 and the first results were reported 30years
ago [10]. Since then the survival of CF patients has improved
and the age distribution has changed significantly. New
antibiotics with anti-S. aureus activity have been introduced.
It is therefore important to evaluate this treatment strategy as
well as the short-term effect of anti-staphylococcal antibiotic
treatment on lung function and BMI.
2. Materials and methods
2.1. Patients and study design
This study is a single-centre cohort study, which was
conducted from 01.01.2008 to 31.12.2009. All CF patients
treated at the Copenhagen CF Centre were eligible for the study;
302 in 2008 and 298 in 2009. All samples of airway secretions
showing a positive culture of S. aureus and the corresponding
antibiotic treatment was retrieved from the CF database.
Ethics: according to Danish regulations this study did not
need approval from an ethics committee.
2.2. General care
All CF patients were seen once a month in the outpatient
clinic where the clinical status and microbiological status were
evaluated as previously described [11].
2.3. Microbiological methods
The methods have been described in details elsewhere [12].
In brief, a sputum or lower respiratory tract secretion sample
obtained by endolaryngeal suction or bronchoalveolar lavage
(BAL) was examined. The specimens were evaluated by
microscopy of Gram-stained smears and cultured on chocolate
agar, 5% horse blood agar, 7.5% NaCl glucose agar, modified
Conradi/Drigalski agar selective for Gram-negative rods, BSSA
agar (Biomerieux), Sabouraud agar pH 4.0, and a 15cm
primary antibiotic susceptibility 5% horse blood agar plate with
the following antibiotic containing tablets: colistin, ciprofloxacin,
tobramycin, piperacillin–tazobactam, aztreonam, imipenem,
meropenem, ceftazidime (Neosensitabs, Rosco, Copenhagen,
Denmark)—which also functions as a selective medium—for
48–72h at 37°C. The 5% blood agar and the chocolate agarplates were incubated in 5% CO2. Specimens which by
microscopy contained areas with bacteria in relationship to
mucus, cylinder epithelial cells and leukocytes were evaluated as
originating from the lower respiratory tract, whereas specimens
containing only squamous epithelial cells were evaluated as
originating from the pharynx and not representative of the lower
respiratory tract. Different phenotypes of each CF pathogenic
species including S. aureus and different antibiotic susceptibility
patterns on the primary susceptibility plate were further examined
and identified and a secondary susceptibility to antibiotics was
done on the isolates.
2.4. Eradication strategy against S. aureus: chemotherapy and
Spa-typing
No prophylactic anti-staphylococcal antibiotic chemotherapy
is used at the Copenhagen CF centre.
Treatment indication for S. aureus is the detection of
S. aureus both by microscopy and culture in secretions from the
lower respiratory tract (sputum, endolaryngeal suction or BAL)
regardless of the patient's clinical condition [10]. However if
the patient was showing signs of increased symptoms the
treatment will be initiated on culture results only. Susceptibility
testing is always used to guide the treatment.
Treatment regimens:
1) Standard regimen: this regimen was used in the first and
second time a S. aureus isolate was cultured, and consists
of the following oral treatment: two weeks of oral fusidic
acid in combination with dicloxacillin or with amoxicillin+
clavulanic acid if indicated by the presence of other path-
ogens such as H. influenzae. To delay the renal excretion
of the beta-lactam antibiotics probenecid is added to the
regimen.
2) Prolonged regimen: should the standard treatment fail to
eradicate the S. aureus infection, oral antibiotic is prescribed
for more than 14days, and most often consists of one month
of fusidic acid in combination with dicloxacillin followed by
twomonths of dicloxacillin as a monotherapy and probenecid,
or one month of fusidic acid or rifampicin or clindamycin or
linezolide in combination with dicloxacillin and probenecid
followed by twomonths of dicloxacillin as a monotherapy and
probenecid.
3) Penicillin allergy regimen: if the patient is allergic to penicillin
one of two 14day oral regimens are considered. Either a
combination of clindamycin and fusidic acid or azithromycin,
or a combination of clarithromycin and rifampicin. If necessary,
this regimen is prolonged.
4) Other regimens: If the patients receive antibiotics against
other bacteria e.g. P. aeruginosa, other combinations are
prescribed, e.g. nebulized tobramycin in addition with a
broad-spectrum beta-lactam antibiotic with or without fusidic
acid according to antibiotic susceptibility.
5) Regimen in case of MRSA: treatment consists of a com-
bination of two antibiotics according to susceptibility testing
in most cases fusidic acid and rifampicin or clindamycin or
linezolide.
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All S. aureus isolates were Spa-typed at the Department of
Hospital Infection at the State Serum Institut, Copenhagen [13].
Spa-typing replaced phage typing in 2007, after a one year
period where both typing systems were used in order to
maintain concordance between the two typing systems [14]. In
all cases the results were in accordance.2.5. Definition of frequency/prevalence/incidence, chronic
infection and therapy outcomes
The patient was defined as intermittent infected with S.
aureus if one or more, but less than 50% of monthly cultures
per year were positive. The yearly prevalence of infected
patients was calculated as the number of patients with one or
more positive S. aureus samples divided by the total number of
patients treated at the centre the corresponding year. The yearly
incidence of new chronically infected patients was calculated as
the number of patients who became chronically infected that
year, and were not chronically infected the year before, divided
by the number of patients at risk=the number of patients
without chronic S. aureus infection at the beginning of the
year+the number of new CF patients without chronic S. aureus
infection who were admitted to the CF Centre that year. The
yearly prevalence of chronically infected patients was calculat-
ed as the number of patients who harbored the bacteria
chronically that year divided by the total number of patients
treated at the center that year.
If S. aureus was absent from the lower respiratory tract at the
next visit to the clinic or if the Spa-type was different the
treatment was regarded successful even if re-infection with
another Spa-type had occurred. If S. aureus with the same
Spa-type was present, the treatment was considered unsuccess-
ful. These principles—previously relying on phage typing—
were unchanged since the founding of the CF Centre [10].
Patients were defined as chronically infected if S. aureus
was present in 50% or more of the monthly cultures of the
particular year, which is a modified Leeds criterion used for
P. aeruginosa infection [15]. Only patients with at least 4
yearly samples were evaluated for being chronically infected.2.6. Clinical effectiveness of anti-staphylococcal antibiotic
chemotherapy
Patients were included in this part of the study if S. aureus
was the only microorganism cultured and if clinical data on
lung function, weight and height from 7days before and up to
30days after the end of the oral S. aureus treatment, was
available. During 2009, the clinical effectiveness of anti-
staphylococcal antibiotic chemotherapy was assessed in a
subgroup of otherwise clinically stable patients not exhibiting
any exacerbations according to Fuchs criteria [16] and who
fulfilled the previously described treatment criteria. The
percentage change in the absolute values of FEV1 and FVC
[17,18], and z-score BMI was calculated.2.7. Statistics
One-way ANOVA was used for the between group com-
parison, and the t-test for paired samples was used for the
within group comparison. Level of significance is p≤0.05
(two-tailed). To see if there was a difference in the number of
patients in different age groups who received anti-S. aureus
chemotherapy we used the χ2 test. All statistical analyses were
made using GraphPad Prism version 5 for Windows 7 or SPSS
12.0 for Windows.
3. Results
3.1. S. aureus prevalence
The prevalence of CF patients with S. aureus positive cultures
during the study period was unchanged; 142 out of 302 patients
(47%) in 2008 and 141/298 (47%) in 2009, respectively.
A total of 168 CF patients, with a median (range) age of 16
(0 to 47) years were culture positive for S. aureus at one or
more occasions over the two year period. Sixty percent of them
were children under the age of 18years. The median (range)
number of positive cultures per patient per year was 4 [1–13]
positive cultures per patient per year. A total of 1200 positive
S. aureus cultures were found, of which 540 samples were
confirmed by microscopy in 136 patients with a median (range)
of 3 [1–14] per patient in the two year period.
Ninety-three percent of all children treated at the CF Centre
(100 children out of 108) had at least one positive S. aureus
culture in contrast to only 36% of all adult patients (68 patients
out of 190 patients over 18years of age).
No significant difference was found among the groups
according to the number of positive cultures, but significantly
more patients aged 0 to 18 were infected with S. aureus
compared to the adult patients (pb0.0001).
Small colony variants (SCV) have not been found in the
present study.
Demographic data is summarized in Table 1.
3.2. Susceptibility of S. aureus isolates
A total of 1200 S. aureus isolates, divided in 170 different
strains were found in the 168 patients based on Spa-types. The
majority (88.7%) of the isolates were penicillin resistant; resistance
to other antibiotics was rare (Table 2).
MRSA was only found in two sputum samples from two
different patients, these were only cultured once from each
patient and did not belong to the same Spa-type.
3.3. Treatment effectiveness
A total of 577 anti-staphylococcus treatments were pre-
scribed to 138 patients, with a median (range) of 3 [1–13]
treatments per patient in the two year period. In total the
S. aureus infection was eradicated at the next clinic visit in 49%
of the treatments and in 12% of cases the initial strain was
eradicated but the patient was re-infected with another strain
Table 1
The demographic data of the whole CF population treated at the center, the patients with S. aureus positive cultures and the 65 CF patients evaluated for the clinical
effect of the antibiotic treatment on S. aureus cultures.
Copenhagen CF population
2009
S. aureus culture positive patients
2008–2009
Treatment group available for
clinical evaluation
Gender M/F 146/152 79/89 41/24
Genotype
Delta F 508 homozygote 202 (68%) 118 (70%) 44 (68%)
Delta F 508/other 85 42 18
Other/other 8 4 2
Unknown 3 4 1
Age median (range) years 24 (0 to 62) 16years (0 to 47) 16.5years (4.8 to 39.2)
Age 0–18years 108 (36%) 100 (60%) 39 (60%)
Age N18years 190 (64%) 68 (40%) 26 (40%)
FEV1% median (range) a – – 85.3% (39.9 to 117.2)
FVC% median (range) a – – 95.2% (64.8 to 135)
z-score BMI median (range) – – −0.21 (−3.8 to 2.4)
a Percentage of predicted value.
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penicillin allergy regimen was significantly more effective in
eradicating S. aureus (p=0.012) (Table 3).
3.4. Chronic S. aureus infection
Repeated and prolonged treatments eventually resulted in the
eradication of S. aureus in majority of the patients. However, 41
patients (14%), 95%CI; 4.1 to 10.0 fulfilled the criteria of chronic
infection with S. aureus in 2008 and 42 patients or 14%, (95% CI;
6.1 to 12.9) in 2009. Only 24 (8%) of the patients were chronically
infected during the entire study period and the yearly incidence of
new chronically infected patients in 2009 was 7% (17 patients).
Only 7 and 9% of the patients (respectively each year during the
study) were infected with a strain with an unchanged Spa-type and
as such confirmed to be truly chronically infected according to our
definition. Only 5% of the infected patients were infected with a
strain with an unchanged Spa-type during the entire study period.Table 2







Fully susceptible 81 (7) 38 (23) 30
P 1065 (89) 154 (92) 156
P+T 37 (3) 14 (8) 13
Azi/Cli 312 (26) 51 (30) 53
P+T+Azi/Cli 12 (1) 4 (2) 6
P+R 50 (4) 17 (10) 16
P+R+Azi/Cli 30 (3) 8 (5) 9
P+R+Azi/Cli+F 6 (0.5) 1 (0.6) 2
P+F 21 (2) 9 (5) 9
P+G+Azi/Cli 2 (0.2) 2 (1) 2
P+T+R+Cli/Azi 6 (0.5) 2 (1) 2
Met 1 (0.1) 1 (0.6) 1
Met+Cli/Azi 1 (0.1) 1 (0.6) 1
* Some of the strains were resistant not only to penicillin and thereby were
counted more than once. Penicillin (P), tetracycline (T), rifampicin (R),
gentamicin (G), fusidic acid (F), azithromycin (Azi), clindamycin (Cli),
methicillin (Met).3.5. Effectiveness of anti-staphylococcal antibiotic chemotherapy
During 2009, 146 anti-S. aureus treatments in 65 patients
were available for clinical evaluation which amounted to a
median (range) of 2 [1–5] treatments per patient. The median
(range) FEV1 of the patients were 85.3% of the predicted (39.9
to 117.2%). Sixty percent of the treated patients were children
under 18years of age (Table 1). FEV1 increased after treatment
in 103 patients (70%) with a median of 5.6%, while the
remaining 43 patients (30%) showed a decrease, with a median
of −3.8% (Fig. 1). In total, anti-staphylococcal antibiotic
chemotherapy accomplished a small, but statistically significant
median (range) improvements in both FEV1% predicted of
3.3% (−25% to 36%, pb0.0001), and FVC of 2.2% (−39 to
40%, p=0.001). z‐score BMI was unchanged.
4. Discussion
During the two year period the prevalence of S. aureus was
stable at around 47%, with 14% of patients being chronically
infected. In general S. aureus was highly susceptible and theTable 3
Number of antibiotic treatment regimens, percentage of successful treatments in









Number of treatments 205 156 81 137 577
Number of patients 83 62 44 72 138
Successful eradication (%) 97 (47) 69 (44) 44 (54) 75 (55) 285 (49)
Successful eradication of
original strains (%) a
125 (61) 83 (53) 57 (70) 88 (64) 353 (61)
Re-infection with another
strain (%) b
28 (14) 14 (9) 13 (16) 13 (9) 68 (12)
a If S. aureus was absent from the lower respiratory tract at the next visit to
the clinic or if the Spa-type of cultured strain was different the treatment was
regarded successful.
b Original strain eradicated, but re-infected with another strain.
Fig. 1. Effect of anti-staphylococcal antibiotic therapy on FEV1 (% predicted).
Change in lung function is shown on the x‐axis and each single treatment is
shown as a horizontal bar on the y‐axis.
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prolonged treatments resulted in eradication of the strain. In
2009 the prevalence of any S. aureus isolate from the respiratory
tract of CF patients in USA was 65.8%, of which 23.7% were
MRSA [19,20]. A recently published Belgian study reported 67%
of their patient population as chronically infected with S. aureus
and 18% harboring MRSA strains [21]. This is in contrast to
findings in our patient population with only 0.3% of patients
harboringMRSA strains and none with chronic MRSA infection.
The low prevalence of MRSA in our CF population corresponds
well with the low prevalence of MRSA in the general Danish
population [22].
The prevalence of macrolide and penicillin resistant S. aureus
strains was higher in our CF Centre patients compared with the
prevalence of isolates from Danish bacteraemic non-CF patients.
Penicillin resistant S. aureus was seen in 77% of the strains from
non-CF patients vs. 89% of the cultures in the CF population.
The difference was even more marked for azithromycin resistant
S. aureus strains; 4% in non-CF patients vs. 26% in CF patients
[23]. High macrolide resistance has been previously reported and
ascribed to macrolide antibiotics used in chronic P. aeruginosa
lung infection [24,25]. In the present study the majority of
S. aureus positive cultures were found in the children population
(60% in age group 0–18years). Since the prevalence of chronic
P. aeruginosa infected CF children is very low in Denmark (6%)
[26] the high macrolide resistance cannot be explained by
macrolide use for chronic P. aeruginosa treatment but may becaused by the use of macrolides and clindamycin to treat e.g.
S. aureus infections in CF children.
There is some experimental evidence that exoproducts of
P. aeruginosa enhance SCV formation and conversely SCV
growth provides a survival advantage for S. aureus in the
presence of P. aeruginosa infection [9]. The very low prevalence
of chronic P. aeruginosa infection among CF children in
our study population together with the minimal usage of
sulphamethoxazole+trimetoprim can probably explain why
small colony variants (SCV) are not seen in the present study
since our methods are adequate for culturing SCV.
The treatment strategy (initial, repeated and prolonged
treatments) has proved to be very efficient since less than
15% of the patient population became chronically infected with
S. aureus. This result is similar to previously published results
by our CF Centre three decades ago [10] and similar to the
prevalence of chronic S. aureus reported from the UK where
prophylactic anti-staphylococcal treatment is recommended
[27]. The prophylactic antibiotics for S. aureus are not used in our
centre since all patients are investigated eachmonth and all patients
with a positive S. aureus culture from the secretion obtained from
the lower respiratory tract are prescribed anti-S. aureus treatments.
After 12% of the treatments re-infection with another strain
occurred at the next visit at the clinic and treatment was then
repeated.
Prophylactic treatment of S. aureus has been associated with
an increased prevalence of Gram negative bacteria such as
P. aeruginosa [10,11] and yet, without employing prophylactic
antibiotics for S. aureus and despite frequent use of anti-S. aureus
antibiotics, the prevalence of chronic P. aeruginosa infection in
our population is very low [26].
S. aureus isolates may persist in CF patients over years. In a
large survey of S. aureus in six French hospitals, 85 of 238
patients (30%) who were culture positive for S. aureus, had
three or more consecutive isolates over at least 6months and
48% of the subjects harbored the identical isolate as shown by
pulse field gel electrophoresis up to 28months. Data from two
large randomized controlled trials noted the persistence of
S. aureus for a median of 37months with most of the patients
harboring a single clone [28,29].
In the present study 14% (7% with persistent Spa-type) of
our patients fulfilled the criteria of chronic infection and the
chronic infection persisted in only 8% (5% with the same
Spa-type) of the patients, indicating that chronic S. aureus
infection persisted only in a few patients whereas a few new
chronic infections occurred every year.
Antibiotic treatment of any relevant microorganism, ignoring
the presence or absence of respiratory symptoms has been our
policy since the establishment of our CF centre in 1968 [10].
However, the overall short term influence on lung function and
BMI of our early treatment policy has not previously been
reported. We investigated the short term effectiveness of the
treatment in otherwise clinically stable patients with positive
S. aureus infections, and found a significant effect on pulmonary
function for FEV1 and FVC, respectively, similar to the results of
early eradication of P. aeruginosa colonization [30]. Further-
more, a BAL study assessing inflammation as a reflection of
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eradication programs for S aureus [31].
Ranganathan et al. [4] reported an association between
infection with S. aureus and lower BMI, and that the use of
anti-staphylococcal antibiotics lead to increased BMI and
furthermore, increase in childhood BMI has been shown to be
associated with better lung function [32] supporting the policy
to treat S. aureus infection even in apparently asymptomatic CF
patients.
The present study has several limitations. The study period is
only two years and the patient population is small but homogenous
with respect to examination and treatment policy. The effect on
lung function and BMI is only evaluated after a single two week
treatment. Furthermore, the results cannot be compared across the
different CF Centres due to the lack of a commonly appreciated
definition of chronic infection, different frequency of sputum
culture—once a year against once a month—and different
treatment strategies [6,12,33]. However, we have used the Leeds
definition of chronic infection in CF, which was introduced for the
description of P. aeruginosa infections [15] which gives nearly the
same results as our previously published definition (continuous
presence of S. aureus for 6months) [10].
A prospective study of longer duration in a larger patient
population is needed to confirm possible long-term benefits of
the eradication treatment in a clinically stable CF patient.
In conclusion, S. aureus was frequently found in the lower
respiratory tract of Danish CF patients. Use of a stepwise
two-drug antibiotic combination therapy strategy results in a
high level of eradication with a prevalence of chronic S. aureus
infection b15%, which has been unchanged for decades as well
as a few resistance problems and significant short term effects
on lung function.Conﬂict of interest statement
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